News - Circle Pharma

Background Publications on Macrocycles

Our Science

The Promise of Macrocycles

Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut. labore et dolore magnam aliquam quaerat voluptatem.

Circle Pharma to present Trials in Progress poster on CID-078, a first-in-class cyclin A/B inhibitor, at the ASCO 2025 Annual Meeting

May 12, 2025

Anti-cancer effect of Cyclin A/B RxL inhibitors is mediated in part by disruption of the ATR/CHK1 DNA repair pathway

April 29, 2025

Circle Pharma to Present Late-Breaking Data at AACR 2025 Demonstrating Mechanism of Action for Novel Cyclin A/B RxL Inhibitors

April 22, 2025

Circle Pharma to Present at the Upcoming Investor Conferences

March 31, 2025

CID-078, a first-in-class oral cyclin A/B-RxL inhibitor, elicits anti-tumor activity in breast cancer patient-derived xenograft models

December 9, 2024

Circle Pharma Presents Promising Preclinical Data on First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor CID-078 at the San Antonio Breast Cancer Symposium 2024

December 9, 2024

CID-078, a First-in-Class Oral Macrocycle CyclinA/B-RxL Inhibitor, Demonstrates Anti-Tumor Activity in E2F-driven Cancers

October 23, 2024

Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium

October 23, 2024

Circle Pharma Announces First Patients Dosed in Phase 1 Clinical Trial of First-in-Class Oral Cyclin A/B RxL Inhibitor CID-078 for Advanced Solid Tumors

October 15, 2024